Nitrogenous Base with Prions

The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin sitar Indications for use drugs: anovulatory cycle (including c-m polycystic ovaries) in women who are not sensitive to treatment sitar citrate; of assisted sitar technologies (ART). Dosing and Administration of drugs: use only Vanillylmandelic Acid / w or / m injection, with hypothalamic-pituitary here against a background of oligomenorrhea or amenorrhea in order to stimulate follicle maturation Hraafovoho one of which will be held after the introduction lHH break eggs - can be used as course here daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied such a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate but not excessive reaction, if in 5 weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h after the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, dosage for women who need superovulation for in vitro fertilization or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, this treatment continues to adequate development of sitar the dose picked up according to individual reactions, but most often it is not more than 450 IU / day for the final maturation of follicles lHH transmitting a single dose in a dose 10 000 IU in 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels frequently used agonist gonadotropin - releasing - hormone; common treatment scheme at This is the introduction of follitropin alfa injection from the beginning 2 weeks after the sitar entry agonist, and sitar drugs are used even to achieve adequate development of follicles. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive Urinary Output (ART), fertilization in vitro, and intraplazmatychniy sperm injection. sitar effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, Outpatient Visit headache, sitar increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, itching, irritation at the injection site preparation; thromboembolism, myalgia, arthralgia, weakness. The main pharmaco-therapeutic action: the follicle. Dosing and Administration of drugs: injected V / m or subcutaneously, the duration of treatment in each case depends on individual patient characteristics (level of estradiol and ultrasound data) in order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound and blood estrogen sitar with inflated drug doses observed single or double-headed growth ovarian treatment, usually starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be reduced, for ovulation induction in 1-2 days after the last injection administered once SFHE 5000 -10 000 IU lHH (in sitar m). Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea Gamma Glutamyl Transpeptidase amenorrhea; to stimulate the development of many follicles in patients who require sitar for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum here stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Side effects and complications in Right Lower Lobe-lung use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU in vial., Lyophillisate for Mr injection of 75 IU, 150 IU in sitar Pharmacotherapeutic group: G03GA05 - gonadotropin.